Manufacturing Intelligence — July 29, 2026
| GSK is internalizing commercial scale-up at its Ware site while winding down Stevenage by 2029 and cutting $2.5 billion in annual supply-chain and mature-product costs. Eli Lilly tops Contract Pharma’s 2026 Top 20 ranking of U.S. manufacturing investment, driven by GLP-1, ADC, and cell-and-gene-therapy capacity buildout.
Today’s top developments:
|
What to Watch
- GSK supply-chain restructuring detail — GSK’s next operational update should reveal which sites face rationalization or divestment under the $2.5 billion savings plan; any site closures, technology transfers, or expanded CDMO outsourcing of mature product lines would open meaningful inbound opportunity for specialty manufacturers and asset acquirers, with European API capacity holders most exposed.
- Hengrui/Elevar re-inspection and PAI risk — the outstanding July 3 Form 483 at the Dongjin finished-product facility must be cleared before the camrelizumab-plus-rivoceranib combination can advance; watch for FDA re-inspection timing and whether HLB stands up a separate U.S. CMO base to break the repeated single-site manufacturing dependency.
- APAC biologics capacity coming online — AGC Biologics’ Yokohama site formally opening on the back of a pre-signed nine-figure contract tests whether pre-commercial capacity commitments become the standard playbook; ramp and qualification milestones will indicate how quickly Asia-Pacific supply diversification absorbs sponsor demand.
- ADC supply-chain buildout pace — as Lonza’s Visp ADC expansion and competing HPAPI and conjugation capacity come online through 2026–2027, utilization and pricing signals will reveal whether the current HPAPI bottleneck eases or persists into 2028 as late-phase ADC pipelines scale commercially.
This brief highlights the edition’s top stories. Read the full July 29, 2026 edition → for all stories and analysis — or browse the Manufacturing Intelligence archive.